Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label, multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects with Advanced Solid Tumours or with B-cell Malignancies and in Combination with Temozolomide(TMZ) or with Carboplatin and Paclitaxel in Subjects with Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

An open label, multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects with Advanced Solid Tumours or with B-cell Malignancies and in Combination with Temozolomide(TMZ) or with Carboplatin and Paclitaxel in Subjects with Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Jun 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Stenoparib (Primary) ; Carboplatin; Paclitaxel; Temozolomide
  • Indications Advanced breast cancer; B-cell lymphoma; Colorectal cancer; Lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Eisai Co Ltd

    • Most Recent Events

    • 11 Jun 2020 Primary endpoint (Phase 1 To determine the maximum tolerated dose of E7449 as a single agent) has been met.
    • 11 Jun 2020 Results published in the British Journal of Cancer.
    • 05 Jun 2018 Results assessing 2X-121 (E7449) as monotherapy in patients with advanced solid tumors and results of a biomarker analysis, presented at the 54th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top